Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Cambridge Cognition inks strategic partnership with ActiGraph

(Sharecast News) - Brain health specialist Cambridge Cognition announced a strategic partnership with ActiGraph, a provider of wearable technologies tailored for clinical trials, on Wednesday. The AIM-traded firm said the collaboration was intended to yield a comprehensive suite of assessments, offering a holistic perspective on both mental and physical capabilities.

At the core of the partnership was ActiGraph's 'Accelerant' partnership programme, which was intended to propel the use of digital health technologies (DHTs) within clinical development by streamlining access to raw data streams for clinical research organisations (CROs) and technology vendors.

In the context of the new alliance, Cambridge Cognition said it and ActiGraph would use their expertise in digital data collection to augment assessment capabilities within central nervous system (CNS) trials, particularly in domains marked by significant unmet needs such as schizophrenia and dementia.

Cambridge Cognition said it would bring its suite of touch-screen and voice-based digital assessments to the table, known for their precision and sensitivity in gauging cognition and other indicators of brain health.

"CNS disorders are characterised by a host of heterogeneous symptoms which impact daily life, but that are often inadequately addressed by existing treatments," said Cambridge Cognition's chief scientist Francesca Cormack.

"Our partnership with ActiGraph represents an exciting combination of expertise in objective digital measures of actigraphy, speech and cognition that will help accelerate the development of treatments for patients and improve efficiency in clinical trials."

At 1156 GMT, shares in Cambridge Cognition Holdings were down 0.62% at 51.18p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Jubilee Metals starts processing copper feed material at Roan
(Sharecast News) - Jubilee Metals Group announced on Friday that its Roan concentrator facility in Zambia had started processing high-grade copper feed material, marking a key step in its accelerated production plan.
Shuka Minerals progressing proposed acquisition of Kabwe Mine
(Sharecast News) - Shuka Minerals updated the market on its proposed acquisition of Leopard Exploration and Mining and the Kabwe Zinc Mine in Zambia on Friday, following the signing of a conditional share purchase agreement in December.
Losses at Moderna miss estimates, shares ease
(Sharecast News) - Shares in Moderna came under pressure on Friday, after fourth-quarter losses at the US biotech were bigger than expected.
Helical joint venture secures funding for City development
(Sharecast News) - Helical announced on Friday that, in joint venture with Places for London, it had secured a £125m development financing facility from HSBC to fund the construction of 10 King William Street, an over-station office scheme above Bank station in the City of London.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.